| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Bimatoprost acid targets the prostaglandin F receptor (FP receptor), a G protein-coupled receptor that mediates the effects of prostaglandin F₂α. The compound is a potent and selective FP receptor agonist. By activating the FP receptor, bimatoprost acid increases uveoscleral outflow of aqueous humor, reducing intraocular pressure (IOP). The FP receptor is primarily expressed in the ciliary body and trabecular meshwork of the eye. Activation of the FP receptor leads to the remodeling of the extracellular matrix in the ciliary muscle and sclera, facilitating the drainage of aqueous humor. Bimatoprost acid is the active metabolite responsible for the ocular hypotensive effects of bimatoprost.
|
|---|---|
| ln Vitro |
In vitro, bimatoprost acid binds to the prostaglandin F receptor (FP receptor) with high affinity and potency. It is a potent and selective FP receptor agonist. The compound activates FP receptor signaling, leading to increased intracellular calcium and activation of downstream signaling pathways. In cell-based assays, bimatoprost acid treatment results in FP receptor-mediated responses, such as changes in cell morphology and gene expression. The compound's high affinity for the FP receptor and its selectivity over other prostaglandin receptors make it a valuable tool for studying FP receptor function.
|
| ln Vivo |
In vivo, bimatoprost acid is the active metabolite responsible for the ocular hypotensive effects of bimatoprost. By activating the FP receptor in the ciliary body and trabecular meshwork, bimatoprost acid increases uveoscleral outflow of aqueous humor, reducing intraocular pressure (IOP). The compound is used clinically in the treatment of glaucoma and ocular hypertension. Bimatoprost is administered as a prodrug that is hydrolyzed to bimatoprost acid in the eye. The compound's ocular hypotensive effects are well-documented in clinical studies.
|
| Enzyme Assay |
In vitro receptor binding assays for bimatoprost acid involve measuring its binding affinity to the prostaglandin F receptor (FP receptor). The receptor is incubated with a radiolabeled ligand and varying concentrations of bimatoprost acid. The displacement of the radiolabeled ligand is measured, and the IC₅₀ or Ki value is calculated. The compound's selectivity for the FP receptor over other prostaglandin receptors is assessed using similar assays. These assays confirm the compound's mechanism of action as an FP receptor agonist.
|
| Cell Assay |
In vitro cell-based assays for bimatoprost acid evaluate its effects on FP receptor-mediated signaling. Cells expressing the FP receptor are cultured and treated with bimatoprost acid. Receptor activation is assessed by measuring intracellular calcium levels using fluorescent dyes. Downstream signaling pathways, such as MAPK and Akt, are evaluated using Western blot. Cell morphology changes are assessed by microscopy. These assays confirm the compound's functional activity as an FP receptor agonist.
|
| Animal Protocol |
In vivo animal experiments for bimatoprost acid are typically conducted in animal models of ocular hypertension. The compound is administered topically to the eye, and intraocular pressure (IOP) is measured over time. The compound's effects on uveoscleral outflow are assessed. Pharmacokinetic studies are conducted to determine the compound's distribution and metabolism in ocular tissues. Comprehensive in vivo studies are available from clinical development.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for bimatoprost acid are available from clinical studies of bimatoprost. Bimatoprost is administered as a prodrug that is hydrolyzed to bimatoprost acid in the eye. The compound has a molecular weight of 390.52 g/mol. After topical administration, bimatoprost acid reaches therapeutic concentrations in the aqueous humor. The compound is metabolized in the liver and excreted in urine and feces. Comprehensive PK data are available from pharmaceutical studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of bimatoprost acid has been evaluated in preclinical and clinical studies. The compound is generally well-tolerated at therapeutic doses. Common side effects include conjunctival hyperemia, ocular itching, and changes in eyelash growth. The compound should be used under medical supervision. Comprehensive toxicological studies are available from clinical development. Bimatoprost acid is the active metabolite of bimatoprost, which is approved for the treatment of glaucoma.
|
| References | |
| Additional Infomation |
17-Phenylacetyl-trinorprostaglandin F2α is a prostaglandin Fα compound belonging to the latanoprost free acid group, and it has a double bond at position 13. It is a metabolite functionally related to latanoprost free acid. Bimatoprost acid has been reported in Trypanosoma brucei, and relevant data are available.
Bimatoprost acid (17-phenyl trinor PGF2α) is the active, free acid metabolite of bimatoprost, a synthetic prostaglandin F₂α analog used in the treatment of glaucoma and ocular hypertension. It has a molecular formula of C₂₃H₃₄O₅ and a molecular weight of 390.52 g/mol. Bimatoprost acid is a potent agonist of the prostaglandin F receptor (FP receptor). By activating the FP receptor, it increases uveoscleral outflow of aqueous humor, reducing intraocular pressure. Bimatoprost acid is the pharmacologically active species responsible for the ocular hypotensive effects of bimatoprost. |
| Molecular Formula |
C23H32O5
|
|---|---|
| Molecular Weight |
388.49718
|
| Exact Mass |
388.225
|
| CAS # |
38344-08-0
|
| PubChem CID |
5283081
|
| Appearance |
White to off-white solid
|
| Density |
1.219g/cm3
|
| Boiling Point |
597.4ºC at 760mmHg
|
| Flash Point |
329.1ºC
|
| Index of Refraction |
1.616
|
| LogP |
3.095
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
28
|
| Complexity |
509
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
OC(CCC/C=C\C[C@H]1[C@@H](O)C[C@H](O)[C@@H]1/C=C/C(CCC1C=CC=CC=1)O)=O
|
| InChi Key |
YFHHIZGZVLHBQZ-KDACTHKWSA-N
|
| InChi Code |
InChI=1S/C23H32O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,14-15,18-22,24-26H,2,7,10-13,16H2,(H,27,28)/b6-1-,15-14+/t18-,19+,20+,21-,22+/m0/s1
|
| Chemical Name |
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]hept-5-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~257.4 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5740 mL | 12.8700 mL | 25.7400 mL | |
| 5 mM | 0.5148 mL | 2.5740 mL | 5.1480 mL | |
| 10 mM | 0.2574 mL | 1.2870 mL | 2.5740 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
